In this study we investigated the neurochemical identity of the arcuate cells activated following GH-releasing peptide-6 (GHRP-6) injection by comparing, on consecutive sections, the distribution c-fos messenger RNA (mRNA) with that of mRNAs for peptides synthesized in arcuate cells, including neuropeptide Y (NPY), GH-releasing factor (GRF), tyrosine hydroxylase, POMC, and somatostatin. Rats bearing chronically implanted jugular catheters were injected with either 50 g GHRP-6 or vehicle. Thirty minutes later they were terminally anesthetized and perfused with fixative. Paraffin-embedded sections of 7 m thickness were processed using in situ hybridization for either c-fos mRNA or mRNAs for the neurochemical markers. In GHRP-6-treated rats the mean (Ϯ SEM) number of cells expressing c-fos mRNA in the arcuate nucleus (23 Ϯ 2 cells/section per rat; n ϭ 5) was significantly higher than for vehicle-treated controls (2 Ϯ 1 cells/section per rat; n ϭ 5; P Ͻ 0.001, Mann-Whitney U test). Superimposed camera lucida maps indicated that, in GHRP-6-injected rats, neurochemically identifiable cells expressing c-fos mRNA also express NPY mRNA (51 Ϯ 4%), GRF mRNA (23 Ϯ 1%) tyrosine hydroxylase mRNA (11 Ϯ 3%), POMC mRNA (11 Ϯ 2%), or somatostatin mRNA (4 Ϯ 1%). Thus, the majority of cells expressing c-fos mRNA following GHRP-6 injection are NPY and GRF-containing cells. (Endocrinology 138: 771-777, 1997) 
T HE SYNTHETIC hexapeptide GH-releasing peptide-6 (GHRP-6) stimulates GH secretion (1) by a direct pituitary action, via a mechanism that is different to that of the endogenous GH-releasing factor GRF: GHRP-6 binds to a different receptor site to GRF (2) and is coupled to a different intracellular signaling system (3). Additionally, GHRP-6 has a central site of action that includes the activation of a subpopulation of hypothalamic arcuate neurons, as reflected by increased electrical activity and by the immunocytochemical detection of Fos, the protein product of the immediate early gene c-fos (4, 5) . The majority of cells expressing Fos protein following GHRP-6 injection are located in the ventral arcuate nucleus and display a degree of overlap with the distribution of GRF-containing cells, notably in the ventrolateral portion (4) . That GHRP-6 may act centrally by stimulating GRF secretion was first suggested by Clark et al. in 1985 (6) because GHRP-6-induced GH release was attenuated by the administration of GRF antiserum. Our electrophysiological studies would support this hypothesis because a proportion of the cells activated by GHRP-6 fulfill multiple criteria for identification as GRF neurons (4, 7) . More direct evidence is suggested by studies in sheep, demonstrating increased GRF concentrations in portal blood following systemic injection of the GHRP-6 mimetic hexarelin (8) .
It is unlikely that the sole action of GHRP-6 within the central nervous system is to activate GRF neurons because there is a large synergistic release of GH when GHRP-6 and GRF are administered concomitantly (1) . Both our electrophysiological studies and the functional mapping studies with Fos immunoreactivity have led us to speculate that the cells activated by GHRP-6 may be a heterogeneous population, including cells other than the GRF-containing cells. Notably, in GHRP-6-injected rats, there is a large cluster of Fos-positive cells in the ventromedial aspects of the arcuate nucleus, where few GRF cells have been described (9, 10) . Studies using the retrograde tracer Fluorogold indicate that between 68% and 82% of the cells excited by GHRP-6 project outside the blood-brain barrier, probably at the median eminence and are therefore likely to be neurosecretory neurons (11) , leaving a further 18 -32% that could not be identified as neurosecretory cells. In electrophysiological studies, GHRP-6 has been shown to elicit a predominantly excitatory response in putative neurosecretory cells (that is, cells antidromically identified as projecting to the median eminence); however, of the cells that did not fulfill the criteria for antidromic identification, the predominant response was inhibitory (5) .
In this study, we investigated further the neurochemical identity of arcuate neurons activated by GHRP-6. To main-tain the integrity of the response, we chose to avoid immunocytochemistry because this would require pretreating the animals with the axonal transport inhibitor colchicine to bring levels of neuropeptides to detectable levels. Instead, we used an in situ hybridization protocol in which alternate sections were probed for c-fos messenger RNA (mRNA), and consecutive sections were probed for mRNAs for either GRF, neuropeptide Y (NPY), tyrosine hydroxylase (TH; a marker of dopaminergic cells in this region), POMC, or somatostatin.
Materials and Methods

Animals and preparation of tissue
Adult male Wistar rats of the Babraham Institute colony (250 -400 g BW) were maintained by nonbarrier methods in a controlled environment (14 h light/10 h dark cycle, 21-22 C) and were allowed pelleted food and water ad libitum. Rats were anesthetized with tribromoethanol/ amyl hydrate (10 ml/kg, ip) for placement of iv catheters on the day before the experiment.
On the day of the experiment, conscious rats were injected iv with either 50 g GHRP-6 (Bachem, Saffron Walden, UK; n ϭ 5) or an equal volume (0.2 ml) saline vehicle (n ϭ 5). Thirty minutes later they were terminally anesthetized with sodium pentobarbitone (60 mg/kg BW; ip) and were perfused transcardially with heparinized isotonic saline (5 min) followed by 4% paraformaldehyde in 0.1 m phosphate buffer (PB) (pH 7.4; 15-20 min). This time point was chosen because it is the expected time of c-fos mRNA induction following GHRP-6 injection, corresponding to the subsequent synthesis of the Fos protein that can be detected at 90 min following GHRP-6 injection (4). Brains were removed and dehydrated before paraffin embedding. For each brain, three sets of 10 consecutive coronal sections, 7 m thick, were cut and collected onto subbed slides.
In situ hybridization procedure
For in situ hybridization, single-stranded antisense oligonucleotide probes were made using previously tested sequences. The probe sequences were complimentary to the nucleotides spanning the following coding regions: c-fos (45- (17) . The probes were 3Ј end-labeled using terminal deoxynucleotidyl transferase (Pharmacia, Milton Keynes, UK) and [␣- 35 S]deoxycytidine ATP (NEN Du Pont, Stevenage, UK) to specific activities of 3-5 ϫ 10 6 dpm/pmol and purified using a Sephadex G50 column.
All solutions used until posthybridization washes were made using buffers or water pretreated with 0.1% diethylpyrocarbonate and autoclaved. Following fixation for 30 min with 4% paraformaldehyde in 0.1 m PB (pH 7.4) sections were rinsed twice in 0.1 m PBS before treatment three times with 0.2% glycin followed by 0.25% acetic anhydride in 0.1 m triethanolamine/0.9% NaCl for 10 min at room temperature. Sections were dehydrated through a series of ethanol solutions ending with absolute ethanol. Dried sections were hybridized in the following buffer: 4ϫ SSC (standard sodium chloride-sodium citrate), 50% formamide, 1ϫ Denhardt's solution, 500 g/ml sheared salmon testis DNA, 10% dextran sulphate, and 0.3% ␤-mercaptoethanol.
35 S-labeled probes were used at an approximate concentration of 4 fmol/l, which gave a total of 3 ϫ 10 5 dpm per slide. Each of the probes were successfully competed for by a 100 times excess of the relevant unlabeled oligonucleotide. Hybridization was carried out in a moist chamber overnight at 37 C. Hybridized slides were dipped briefly in 3 washes of 1ϫ SSC at 55 C for 30 min and finally in 1ϫ SSC for 60 min at room temperature. Slides were then washed briefly in 300 mm ammonium acetate, then 70% ethanol and air dried before processing for emulsion autoradiography. Ilford K-5 nuclear track emulsion (Ilford, Knutsford, Cheshire, UK) was used and the slides were exposed in the dark for 9 weeks (c-fos), 5 weeks (NPY), 3 weeks (GRF, somatostatin, and TH), or 2 weeks (POMC). Slides were 
Cell counting and analysis
For each brain, three sets of 10 consecutive sections, including the anterior, medial, and posterior extent of arcuate nucleus, were examined using a bright field microscope coupled to a camera lucida. A statistical comparison (Mann-Whitney U test) was made of the mean number of cells per section expressing c-fos mRNA in the GHRP-6-treated brains with the control brains; for each of the three sets of sections, cells expressing c-fos mRNA were counted unilaterally in the arcuate nucleus in the five sections hybridized with the c-fos probe. The cellular colocalization of c-fos mRNA to neurons expressing mRNAs for the other neurochemical markers was determined by superimposing serial maps of pairs of sections. Colabelled neurons in the adjacent section were identified as those displaying a partial or total overlap in the cluster of silver grains covering the cell cytoplasm. The data are expressed as mean number of cells per section per brain.
Results
In GHRP-6-treated rats the mean (Ϯ sem) number of cells expressing c-fos mRNA (23 Ϯ 2 cells/section per rat; n ϭ 5) was significantly higher than for vehicle-treated controls (2 Ϯ 1 cells/section per rat; n ϭ 5; P Ͻ 0.001, Mann-Whitney U test; Fig. 1 ). The majority of cells expressing c-fos in GHRP-6-injected rats were located in the ventral portions of the arcuate nucleus, in agreement with previous studies using centrally or systemically administered GHRP-6 followed by Fos immunocytochemistry (4, 5) . Occasional scattered cells expressing c-fos mRNA were present in other hypothalamic structures examined, including the neighboring ventromedial nucleus and the periventricular nucleus but there was no evidence of selective activation of discrete populations of cells in these regions by GHRP-6.
The majority of cells expressing GRF or POMC mRNAs were located in the ventral portion of the arcuate nucleus, notably in the ventrolateral part, though POMC neurons could be detected throughout this nucleus (Fig. 2) . NPY cells were scattered throughout the arcuate nucleus with a dense cluster in the most ventromedial aspects. Cells expressing somatostatin mRNA were located predominantly in the dorsomedial and ventromedial arcuate nucleus. A separate population of somatostatin neurons were clearly visible in the periventricular nucleus of the hypothalamus in some rostral sections not included in this analysis. TH mRNA-positive neurons were clustered in dorsomedial and ventrolateral aspects of the arcuate nucleus. The distribution of these neurochemically defined cells was in agreement with those previously described (18, 19 and references therein).
The mean number of cells expressing GRF mRNA was 14 Ϯ 1 per section. Of these, 38% were identified as also containing c-fos mRNA in the consecutive section (Fig. 3A) . Despite the similar distribution and greater number per section (38 Ϯ 3 cells/section) of POMC mRNA-containing neurons, only 6 Ϯ 1% of these also expressed c-fos mRNA (Fig.  3C) . The largest population of neurochemically identified neurons in this study were those containing NPY mRNA (41 Ϯ 3 cells/section). Of these, almost one third (30 Ϯ 3%) also contained c-fos mRNA in the consecutive section (Fig.  3B) . Somatostatin (14 Ϯ 1 cells/section) and TH (14 Ϯ 2 cells/section) mRNA-containing neurons only colocalized c-fos in 7 Ϯ 2% and 14 Ϯ 3% of the cells, respectively (Fig. 4) .
Of the c-fos mRNA-expressing cells that could be neurochemically defined in the consecutive section, 23 Ϯ 1% contained GRF mRNA, 51 Ϯ 4% expressed NPY mRNA, 4 Ϯ 1% expressed somatostatin mRNA, 11 Ϯ 3% expressed TH mRNA, and 11 Ϯ 2% expressed POMC mRNA.
Discussion
In this study, we demonstrated for the first time the neurochemical identity of the major populations of arcuate nucleus neurons activated by GHRP-6. Of the identifiable neurons that express c-fos mRNA following GHRP-6 injection, approximately half also express NPY mRNA and one fifth also express GRF mRNA. Minor populations of cells acti-
Schematic representation of distribution of cells expressing mRNAs for GRF, NPY, TH, POMC, and somatostatin (Som) with cells expressing c-fos mRNA in the arcuate nucleus of a conscious male rat injected with 50 g GHRP-6. Cells expressing neuropeptide markers that could be identified as coexpressing c-fos mRNA on the consecutive section are represented by F, and those not coexpressing c-fos mRNA are represented by E. Three sets of consecutive sections are illustrated that correspond to three different levels of the arcuate nucleus: bregma Ϫ2.12 mm (left), Ϫ2.56 mm (middle), and Ϫ3.14 mm (right) (54) . 3v, Third ventricle.
vated by GHRP-6 included cells containing TH or POMC mRNAs, whereas few expressed somatostatin mRNA.
Recently, Kamegai and colleagues (20) used a similar approach to determine whether cells expressing c-fos mRNA in rats injected with KP-102 (a peptidyl GHRP-6 mimetic) could be identified as expressing GRF mRNA on the consecutive section. Although the proportion of cells expressing c-fos mRNA which were identified as GRF-containing cells correspond to that observed in the present study (23% in both GHRP-6 and KP-102-injected rats), the proportion of GRF cells expressing c-fos mRNA was very different in each case (38% for GHRP-6 injected rats and 20% in KP-102-injected rats) (20) . Thus, it would appear that GHRP-6 and KP-102 activate a subpopulation of GRF cells, that more GRF neurons are activated by GHRP-6 than by KP-102, and that both of these GH secretagogues also activate non-GRF cells in the arcuate nucleus.
The GRF-and TH-containing cells in the arcuate nucleus have accepted adenohypophysiotropic status, and both of these systems project to the median eminence where they release factors into the portal system of capillaries for transport to the anterior pituitary. Thus, activation of GRF-and, to a lesser extent, TH-containing neurons by GHRP-6 is consistent with a previous study demonstrating increased expression of Fos protein in neurons that project outside of the blood-brain barrier and are therefore likely to be neurosecretory (11) . Because as many as 82% of the cells activated by GHRP-6 were found to project outside of the blood-brain barrier, it seems unlikely that the GRF-(and the TH-) containing cells are the only neurosecretory cells activated by GHRP-6. Although NPY is present in portal blood in concentrations that are higher than in the peripheral circulation (21) , there appears to be some doubt as to whether the arcuate NPY cells are true neurosecretory adenohypophysiotropic cells that project to the external zone of the median eminence (22, 23) . In rats treated parenterally with monosodium glutamate (this causes cytotoxic lesion of 80 -90% of arcuate cells that project outside of the blood-brain barrier), there was a depletion of NPY-immunoreactive cell bodies in this region, consistent with the idea that NPY cells project outside the blood-brain barrier. However, monosodium glutamate treatment did not alter the NPY fibers in the external layer of the median eminence, suggesting that these fibers may originate from elsewhere, perhaps as ascending noradrenergic fibers from the brain stem that colocalize NPY (18) . Thus, although the majority of cells activated by GHRP-6 project outside the blood-brain barrier (11) , it remains to be determined whether the NPY population project to the median eminence or whether they are open to the circulation in some other way. In this respect, it is interesting that arcuate NPY neurons are believed to detect circulating levels of leptin (24) . Because the majority of cells activated by GHRP-6 project outside of the blood-brain barrier, it is not surprising that populations of cells in the arcuate nucleus such as the POMC and soma- tostatin-containing cells (which have not been identified as projecting to the external layer of the median eminence) (18, 19) , did not express c-fos mRNA following GHRP-6 injection.
In this study we provide neurochemical evidence to corroborate our hypothesis that the arcuate cells activated by GHRP-6 are likely to be a heterogeneous population of neurons. This hypothesis was first suggested from our electrophysiological studies (in vivo), because it was evident that GHRP-6 injection resulted in a variety of different responses recorded at the cell bodies of arcuate neurons: of the cells antidromically identified as projecting to the median eminence (the putative neurosecretory cells) the predominant response was excitatory and for the arcuate cells not antidromically identified as projecting to the median eminence (the majority of which are unlikely to be neurosecretory cells), the predominant response was inhibitory (5) .
One of the limitations of the present study is that it is not possible to determine to what extent the arcuate cells expressing c-fos mRNA following GHRP-6 injection express more than one of the neuropeptide markers. For example, TH and NPY appear to colocalize with GRF in a subpopulation of arcuate neurons (25, 26) . Thus, activation of GRF neurons by GHRP-6 could account for a small proportion of the c-fospositive cells expressing NPY mRNA and/or the TH mRNA in the present study. The latter is consistent with a previous double immunocytochemical study, demonstrating that approximately 7% of the cells expressing Fos protein following GHRP-6 injection are TH-positive (11) .
Part of the central GH-releasing action of GHRP-6 may be accounted for by increased NPY release into portal blood, because NPY stimulates GH release when administered systemically (27) . When administered by icv injection, NPY inhibits GH secretion (28) , and so increased central release of NPY in response to GHRP-6 injection would be expected to decrease GH secretion. Indeed, increased central release of NPY may account for the decrease in GH secretion observed following intracerebroventricular injection of GHRP-6 in the rat (29) , although this response may be species specific (30) .
The NPY neurons in the arcuate nucleus have been implicated in a number of important physiological mechanisms including the regulation of feeding behavior (31), sexual behavior (32) and in the regulation of various endocrine and metabolic functions (33) (34) (35) . The arcuate NPY cells give rise to a major hypothalamic pathway that sends afferent fibers to the anterior hypothalamus, the preoptic area, the paraventricular nucleus (PVN), as well as the ventromedial and dorsomedial hypothalamus (36, 37) . Multiple daily injections of NPY into the PVN increases daily food intake and body weight (38) . Activation of NPY neurons by GHRP-6 administration may therefore provide a mechanism to explain the increase in feeding behavior in rats following GHRP-6 administration (39) . NPY infused directly into the PVN has also been shown to increase the secretion of both corticosterone and ACTH (40 -43) . In the PVN, there is ultrastructural evidence for NPY-immunoreactive contacts with CRH-immunoreactive cell bodies (44) , suggesting that NPY cells make direct contacts with CRF cells within the PVN. GHRP-6 (and other peptide and nonpeptide mimetics) have also been shown to increase ACTH and cortisol secretion in many species (45) (46) (47) .
Recent studies implicating the arcuate NPY neurons in neuroendocrine GH regulation have focused on their likely role in mediating GH auto-feedback control, because GH receptor mRNA has been located on the arcuate NPY cells (48, 49) . In hypophysectomized rats, GH administration has been shown to induce c-fos expression in NPY neurons in the arcuate nucleus (50) , raising the possibility that the induction of the c-fos gene in response to GHRP-6 could be mediated by a central action of released GH, rather than a direct response to the central action of GHRP-6. This interpretation seems unlikely because GH-deficient dw/dw rats and lit/lit mice show an increase in the number of cells expressing Fos protein in the arcuate nucleus following systemic GHRP-6 injection (51). Furthermore, icv injection of very low doses of GHRP-6 (0.1 g) that do not release GH directly into the lateral ventricle of conscious rats elicits an increase in the number of cells expressing Fos protein in the arcuate nucleus in an identical manner to systemic injection of GHRP-6; both the number and distribution of cells activated were the same, providing evidence to suggest that GHRP-6 acts directly within the central nervous system to activate cells in this region (5) . More recently, we demonstrated that GHRP-6 activates arcuate cells directly, because excitatory and inhibitory responses were recorded at the cell bodies of arcuate neurons in vitro from a slice of arcuate nucleus during bath application of GHRP-6 (52). Collectively these data suggest that GHRP-6 acts within the central nervous system (including a direct action on cells in the arcuate nucleus) to activate neurons in this region (including the NPY and GRF populations), and that the induction of the c-fos gene is not mediated secondarily by increased GH secretion. Now that the GH secretagogue receptor has been cloned (53), it will be important to establish whether the arcuate cells expressing the GH secretagogue receptor include the GRF and NPY populations, and hence, whether the GH secretagogues act directly on these cells.
